MAP2K7 and cancer: AXLhigh melanoma are enriched during BRAF/MEK and PD-1 inhibitor therapy41 and are induced via microenvironmental cues including T-cell-induced inflammatory stimuli (e.g., TNFα)42,43 and cancer-associated fibroblast activity (e.g., TGFß signaling)41,44,45.